FineHeart Secures €83M in Series C Funding to Advance FlowMaker, the Smallest Synchronized Left Ventricular Assist Device

FineHeartBu YiCompleted the first closing of its Series C financing round, with an amount of 35 million euros. This round of financing was led byGroupe Pasteur Mutualité、Groupe Groupe Etchart and European Innovation Council (EIC)AndFH Founders、Lurra、IRDI、Groupe Doliam Group and NACO Investment.

In addition, this financing alsoActivate the European public funding project —— IPCEI Tech4Cure1.FineHeart will start fromIPCEI Tech4Cure1 Project Receives€48 million in funding. Thus, the total amount of this round of financing has reached €83 million.

The financing will accelerate the industrialization process and clinical development of its FlowMaker and establish itself as a future leader of AIMD in Europe.

Investor Evaluation

"Groupe Pasteur Mutualité"Act for health by combining prevention, solidarity, and support for innovation. By supporting FineHeart, we are investing in a technology that has the potential to transform the treatment of severe heart failure, driven by our shared ambition: advancing health for all."

---Thierry Lorente  Groupe Pasteur MutualitéManaging Director

Executive Assessment

"We are delighted to welcome new investors on board with this initial closing. I would like to extend special thanks to Groupe Pasteur Mutualité and the European Innovation Council (EIC) for their crucial contributions, as well as our long-term shareholders, particularly those led by FH Founders, for their unwavering support. Together with IPCEI funding, this financing round reinforces our ambition: to develop disruptive, IP-protected technologies that enable more predictive, personalized, preventive, and participatory healthcare while enhancing Europe's industrial competitiveness and healthcare sovereignty."

---Arnaud Mascarell CEO and Co-founder of FineHeart

FlowMakerAs a new generation of fully implantable left ventricular assist device, its design core lies in maintaining coordinated operation with the natural contraction of the heart. Compared with existing devices,FlowMakerWith less invasiveness, it significantly improves the quality of life for patients while being committed to preserving native heart function.

Compared with existing LVADs,FlowMakerThe battery, connector, and pump are fully implanted together, so there are no wires extending outside the patient’s body, reducing the risk of infection. After implantation, the device is controlled and charged via a belt-like system — akin to wearing a cummerbund — eliminating the need for patients to carry bulky battery packs. In fact, external controllers can be completely removed for several hours, allowing patients to take a bath or engage in other daily activities.

 In addition,FlowMakerImplantation SurgeryVery simple，Using matureSmall Incision Surgery，No need for extracorporeal circulation or bypass required for traditional LVAD implantation.This means that patients will recover much faster and the risk of complications should be lower.MoveAnimal experiments have shown that implantationFlowMakerIt only takes an hour, which is at least three to four times faster than LVAD.

AssumptionFlowMakerIn the early stage of heart failure, implantation is performed rather than waiting until the critical end-stage when LVADs are typically used as a bridge to transplantation. If the patient recovers due to early intervention and cardiac support,FlowMakerCan be easily removed.

• The working frequency is completely synchronized with heart contraction;

• The wires will not fall off from the body, thereby reducing the risk of serious infection and bringing a higher quality of life to patients;

• Including a dedicated programmer that can be fine-tuned according to the patient's specific condition;

• Only two small incisions are required in the chest, without the need for extracorporeal circulation.

FlowMakerThe beating heart is implanted through a mini left thoracotomy and anchored to the apex of the left ventricle via a proprietary dedicated delivery system.